BACKGROUND: Fine-needle aspiration (FNA) is widely accepted in the preoperative management of salivary gland lesions. The proposed Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) aims to standardize reporting terminology. Studies regarding the risk of malignancy (ROM) for the proposed categories continue to evolve. The current retrospective study applied the MSRSGC to assess ROM for salivary gland lesions and focused on the "indeterminate" categories. METHODS: A total of 627 salivary gland FNA specimens obtained from 2011 through 2016 were retrieved, with follow-up available for 373 cases. The original diagnoses were recategorized using MSRSGC by 2 independent cytopathologists as: 1) non-diagnostic; 2) non-neoplastic; 3) atypia of undetermined significance (AUS); 4a) benign neoplasms; 4b) salivary gland neoplasm of uncertain malignant potential (SUMP); 5) suspicious for malignancy (SFM); and 6) malignant.
INTRODUCTION
Salivary gland neoplasms comprise approximately 6.5% of the lesions sampled in the head and neck, and among these, approximately 40% are malignant. 1 The initial diagnostic workup of a salivary gland nodule uses a multimodal approach. Initial imaging using ultrasound guidance (USG) and/or magnetic resonance imaging enables localization of the lesion within the salivary gland and provides information regarding the imaging characteristics, including the contours of the lesion. In addition, imaging assists with surgical planning for larger tumors within the salivary gland. However, to clarify the malignant potential of a lesion, fine-needle aspiration (FNA) remains the preferred diagnostic test. [1] [2] [3] [4] [5] [6] [7] [8] FNA of the salivary gland has gained widespread use and acceptance among clinicians and their patients. In the majority of cases, the salivary gland lesions are easily accessible for FNA, either superficially by palpation or by USG. The technique is minimally invasive and well tolerated by patients without significant 1 complications, and is a cost-effective diagnostic tool with a high sensitivity and specificity of approximately 54% to 98% and 88% to 98%, respectively. 1,9-11 FNA plays a key role in guiding clinical management and provides useful information such as distinguishing between a neoplastic and a non-neoplastic lesion, ascertaining whether a lesion is benign or malignant, and, last, providing prognostic information and a sample for ancillary testing such as molecular studies. 2, 3, [12] [13] [14] Despite the above-mentioned advantages, a few limitations exist, including the lack of architecture with which to assess invasion, the heterogeneity and significant cytomorphologic overlap between salivary gland lesions, and the ever-expanding portfolio of head and neck tumors with continued molecular classification of these tumors. 5, 9, 15 For these reasons, salivary gland cytology continues to remain a challenging area in cytopathology.
In an attempt to address some of these challenges, the American Society of Cytopathology and the International Academy of Cytology recommended a tier-based classification system in 2015. 9, 16, 17 The goals of this system were to standardize salivary gland cytology reporting across institutions and provide a framework for guiding clinical management. Also known as the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), this classification scheme is comprised of 7 diagnostic categories, including non-diagnostic (ND) (category 1), benign nonneoplastic (NN) (category 2), atypia of undetermined significance (AUS) (category 3), benign neoplasm (NB) (category 4a), salivary gland neoplasm of uncertain malignant potential (SUMP) (category 4b), suspicious for malignancy (SFM) (category 5), and malignant (M) (category 6). Since the advent of the system, to our knowledge few studies to date have demonstrated promise in its use for the classification of salivary gland lesions. With the assimilation of more data from multiple institutions, the system will continue to undergo modifications and revisions to improve its predictive capability and downstream management. In the current study, we retrospectively applied the MSRSGC to recategorize salivary gland lesions on cytology in the study institution from the past 5 years.
MATERIALS AND METHODS

Data Collection
A retrospective 5-year search (January 2011-December 2016) of the pathology database for salivary gland FNA specimens at New York-Presbyterian/Weill Cornell Medical Center yielded 627 cases. Among these, 373 cases had clinical and/or surgical follow-up. The lesions were evaluated either by palpation (superficial) or by imaging (USG or computed tomography guidance). All FNAs were performed with 25-gauge needles with an average of 1 to 4 passes performed depending on the size and complexity of the lesion. The first pass typically was used for adequacy assessment and any additional passes typically were used for additional smears, liquid-based cytology and/or cell block preparation, and/or flow cytometry (FC) as required. Smears were air dried and stained with Diff-Quik and/or ultra-fast Papanicolaou (Pap) staining, and alcohol-fixed and stained using the Pap method. The sample also was processed as a Pap-stained ThinPrep (Hologic Inc, Marlborough, Massachusetts) preparation or cell block when possible. Cytotechnologists and/or cytopathologists performed rapid on-site evaluation for all in-house FNA specimens.
Classification
The original cytologic diagnoses of all 627 cases were recategorized independently by 2 pathologists (one of whom was a cytopathology board-certified pathologist and the other a cytopathology board-eligible fellow) into 7 categories, which included: 1) ND; 2) NN; 3) AUS; 4a) NB; 4b) SUMP; 5) SFM; and 6) M. The pathologists were blinded to the final clinical and surgical follow-up. Discordant cases were reviewed by a third pathologist for final categorization. The criteria used for assigning diagnoses to each category have been described previously.
9,16-20
Risk of Malignancy and Overall Risk of Malignancy Calculations
The risk of malignancy (ROM) and the overall risk of malignancy (OROM) for the different categories were calculated as previously described. 9, 15, 21, 22 Briefly, the ROM is defined as the ratio of FNAs with malignant follow-up to the total number of FNAs with follow-up for that category. Similarly, the OROM is defined as the ratio of FNAs with malignant follow-up to the total number of FNAs with or without follow-up for that category.
RESULTS
A total of 627 FNA specimens were identified between January 2011 and December 2016; the cases included 339 females and 288 males (male:female ratio of 1:1.2) with an , and 59 cases to the M category (9.4%). There was near-perfect agreement (626 of 627 cases; 99.8%) with regard to categorization between the 2 independent pathologists. One case remained discordant; this case was a 1.1-cm left parotid tail lobulation with no discrete mass noted on imaging and was interpreted as bland salivary gland acini with no pathologic change. This case was independently categorized by one of the pathologists as ND and by the other pathologist as NN and remained discordant on combined review. A third pathologist (G.C.H.Y.) reviewed the case independently, blinded to the final follow-up, and rendered a classification in the ND category, which was used as the final category for this case.
On histologic or clinical follow-up of a total of 373 cases, 282 cases were benign (75.6%), 85 were malignant (22.8%), and 6 (1.7%) had scant material or demonstrated minute atypia on follow-up and were categorized as "inconclusive." On categorization of these 373 cases, 45 were classified as ND, 98 as NN, 18 as AUS, 121 as NB, 38 as SUMP, 14 as SFM, and 39 were classified as M. Among the 45 category 1 ND cases, 40 had a benign outcome, 3 had a malignant outcome, and 2 were classified as "inconclusive" on follow-up. Of the NN lesions in category 2 ( Fig. 1 ), 88 were found to be benign, 7 were found to be malignant, and 3 were "inconclusive." Of the AUS lesions in category 3, 11 were benign and 7 were malignant. In the category 4a NB cases, 115 were benign and 6 were malignant. Within the category 4b SUMP cases, 24 were benign, 13 were malignant, and 1 case was deemed "inconclusive." Of the category 5 SFM lesions, 1 was benign and 13 were malignant. Finally, in the category 6 M lesions, which included both primary tumors and secondary metastases, 3 were benign and 36 were malignant. The most common benign and malignant diagnoses in each category are listed in Table 1 . The ROMs for the individual categories of ND, NN, AUS, NB, SUMP, SFM, and M were 6.7%, 7.1%, 38.9%, 5.0%, 34.2%, 92.9%, and 92.3%, respectively. Similarly, the OROMs were found to be 4.1%, 3.9%, 18.4%, 3.0%, 21%, 76.5%, and 61%, respectively, for the aforementioned categories (Table 2 ). With the inclusion of the AUS and SUMP categories, the overall sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were 84%, 84%, 94%, and 64%, respectively. When these 2 categories were excluded, the sensitivity, specificity, NPV, and PPV were 79%, 98%, 94%, and 92%, respectively.
The most common benign neoplasm in the current study cohort was pleomorphic adenoma (PA), comprising 16.9% of all cases (Fig. 2) . The most common malignant neoplasm was lymphoma ( Fig. 1) , comprising 28.2% of all malignant cases (3.8% of all cases). Among the 377 aspirates categorized as NN and NB, there were 13 falsenegative cases (3%), which included 5 cases of lymphoma (1 case each of nodular lymphocytic Hodgkin lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, mature B-cell lymphoma, and follicular lymphoma), 4 cases of carcinoma ex PA, and 4 cases of mucoepidermoid carcinoma (MEC) (1 case each of cystic and Warthin-like low-grade MEC and 2 cases of low-grade MEC) ( Table 3) . For the 5 false-negative cases diagnosed as lymphoma, 4 (80%) cases had a sample procured for ancillary studies including FC, whereas 1 case was an outside consult. Among the 4 cases for which material was available for ancillary studies, 2 had insufficient cellularity for FC, 1 case demonstrated a small population of atypical B lymphocytes highlighted on FC only, and 1 case could not definitively exclude lymphoma based on FC findings only. In all 5 cases, given the high clinical suspicion and/or based on the findings of ancillary studies, an excisional biopsy or surgical resection was performed for a definite evaluation. Among the SFM (17 cases) and M (59 cases) categories, there were 4 false-positive cases, which included 2 PAs, 1 Warthin tumor, and 1 case of chronic sialadenitis with squamous metaplasia.
As previously mentioned, the "indeterminate" group are those categories (AUS, SUMP, and SFM) that do not definitely characterize the salivary gland lesion as either benign or malignant. We focused on exploring this cohort of cases further to determine the ROM and the OROM within this cohort and thereby the significance and outcomes (Tables 4 and 5 ). Within the AUS category (18 cases), 11 cases (61.1%) were benign and 7 cases (38.9%) were malignant on follow-up. The most common benign entity under the AUS category was chronic sialadenitis (2 cases; 11.1%), with primary low-grade carcinomas being the most common malignancy (5 cases; 28%). In the SUMP category (38 cases), 24 cases (63.2%) had a benign Original Article
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follow-up, 13 (34.2%) had a malignant follow-up, and 1 case (2.6%) was deemed "inconclusive" on follow-up. Basal cell adenoma was the most common benign neoplasm (7 cases; 18.4%) and low-grade MEC (Fig. 3) was the most common malignant neoplasm in this category (4 cases; 10.5%). Among the SFM cohort (14 cases), respectively (Table 5 ). The surgical and clinical outcomes of the lesions identified within the indeterminate categories also are depicted in Table 5 .
DISCUSSION
FNA has gained popularity and widespread acceptance among clinicians and patients as the first approach in the diagnostic workup of a patient with a new salivary gland lesion. 5, 7, 8, 11, [23] [24] [25] [26] [27] The technique is minimally invasive, rapid, and cost-effective, and can be used efficiently in the outpatient setting. 1, 28 In an effort to streamline the management of salivary gland FNAs, the MSRSGC was published this year. 16, 17, 29, 30 The objective of this classification system is to create a uniform reporting system for salivary gland cytopathology and assist in the effective communication of the results between the pathologist and clinician for cytologic and histologic correlation of cases, and data evaluation and comparison between institutions. Similar to The Bethesda System for Reporting Thyroid Cytopathology, the proposed MSRSGC relies on a 6-tiered classification system that uses a set of criteria for the categorization of lesions with proposed clinical and surgical management suggestions for each category. A recent survey demonstrated that approximately 72% of the participants with expertise in cytopathology favored the creation of a tiered classification system for salivary gland lesions.
31 Prior institutional studies have applied MSRSGC retrospectively to their patient cohorts to establish the ROM for each of the categories. 9, 15, 21, 22 To further bolster the current data available for the MSRSGC, we attempted to retrospectively categorize the salivary gland FNA specimens over the past 5 years from the study institution based on the criteria proposed by the MSRSGC. 16, 17, 20 The sensitivity and specificity for salivary gland FNAs at the study institution were 79% and 98%, respectively, which is in keeping with prior studies demonstrating a sensitivity of between 54% and 98% and a specificity of approximately 88% to 98%. With the inclusion of the AUS and SUMP categories, the sensitivity, specificity, NPV, and PPV in the current study were 84%, 84%, 94%, and 64%, respectively. When those 2 categories were excluded, the sensitivity dropped from 84% to 79%, whereas the specificity and PPV increased (98% and 92%, respectively), correlating with the fact that the majority of the lesions included in the AUS and SUMP categories were benign on follow-up (ROM < 50% for both categories), leading to the underestimation of specificity and PPV when these categories were included. However, the NPV was unchanged at 94%. The inclusion and exclusion of certain "atypical" categories can significantly affect the predictive value of FNA and will need to be defined further as the MSRSGC continues to be refined. In the study cohort, approximately 12% of the cases were classified as nondiagnostic, which was attributed to a lack of adequate cellularity, lack of lesional cells in the aspirate, or lack of adequate passes, such as when the patient was unable to tolerate the procedure. The majority of salivary gland lesions in the study institution were benign (282 cases; 75.6%), which is consistent with other studies. 9, 15 We had 377 benign NN and NB FNA samples with a ROM of 7.1% and 5.0%, respectively. In comparison, Rossi et al and Rohilla et al had a higher ROM for NN at 16% and 17.4%, respectively, whereas the ROM for their NB cases was 6% and 7.3%, respectively.
9,15
Those malignant lesions incorrectly misdiagnosed as benign on FNA, the so-called false-negative FNAs, affect the ROM in these 2 categories. In the current study cohort and that of Rossi et al, 9 B-cell lymphomas predominantly attributed to the false-negative diagnoses in the NN category in comparison to Rohilla et al, 15 in which secretory carcinoma (mammary analogue), low-grade MEC, and carcinoma ex PA contributed to the increase in ROM in their NN category. The addition of ancillary studies such as FC and immunohistochemistry improved the diagnostic capability of FNA for the lymphoid-rich lesions in the NN and NB category. The increase in ROM in our NB category was largely attributed to follow-up diagnoses of carcinoma ex PA (4 cases), whereas 1 case of MEC and 1 case of oncocytic carcinoma contributed to the increase in ROM in the NB category in the study by Rohilla et al. 15 In the study by Rossi et al, 9 the increase in ROM in the NB category was largely the result of low-grade malignancies, most notably MEC followed by epithelial myoepithelial carcinoma and adenoid cystic carcinoma, among others. 9 The overall false-negative rate in our study was slightly lower at 3%, which is otherwise reported as approximately 5% to 15% for salivary gland lesions. 1, 9, 15 The ROMs for the SFM and M categories were 92.9% and 92.3%, respectively, which is within the range specified in other studies and the recently published atlas. 9, 15, 21 Squamous cell carcinoma was the most common malignant diagnosis in the M category, similar to the findings by Rossi et al. 9 We demonstrated a false-positive rate of 7.4%, which is similar to the previously observed false-positive rate of 0% to 10% reported in the literature. 5, 25, 26, 32 The goal of the proposed MSRSGC is to keep the number of FNA specimens labeled as atypical to <10%. In our study, approximately 7% of the salivary gland FNAs were recategorized as AUS, with chronic sialadenitis and benign lymphoid tissue being the most common benign diagnoses and B-cell non-Hodgkin lymphoma and lowgrade carcinomas being the most common malignant diagnoses (Table 3 ). The ROM for the AUS category was 38.9%, compared with 53% in the study by Rossi et al 9 and 100% in the study by Rohilla et al. 15 The differences in the ROM between the current study and others in general could be attributed to differences in practice patterns between institutions; however, in the study by Rohilla et al, 15 the sample size with follow-up in this category was fairly limited (2 vs 18 FNA cases with follow-up), which also could explain the significant difference in ROM between these studies and ours. The ROM for the SUMP category in the current study was 34.2%, with basal cell adenoma and MEC being the most common benign and malignant diagnoses, respectively. In contrast, Rohilla et al demonstrated a slightly elevated ROM of 50%
15
; however, the sample size of their SUMP category was limited as well (2 vs 38 FNA cases with follow-up), which could explain the significant difference in ROM between their study and ours. 15 In a recently published review of the atlas for the Milan system, Rossi et al highlighted the expected ROMs for the 7 categories as follows: 25% for ND, 10% for NN, 20% for AUS, <5% for NB, 35% for SUMP, 60% for SFM, and 90% for M. 17 Within the current study cohort, the ROMs were within the specified range of ROMs for each category highlighted in the atlas, especially with regard to the ND, NN, NB, SUMP, SFM, and M categories. Our ROM for the AUS category, which was 38.9%, was slightly higher than the range of 10% to 35% provided in the atlas. However, between institutions, there is significant variability in practice patterns of assigning atypical diagnoses that reflect differences in the cytopathologists expertise, sampling techniques and procurement using the USG FNA etc. Consistent with this theory, Rohilla et al had a ROM for AUS of 100%, 15 Rossi et al had a ROM for AUS of 43%, 15 and Wang et al reported ROM between 5 different institutions ranging from 0% to 68%. 22 Thus, collectively between the 3 studies, the ROM ranged from 0% to 100%. 9, 15, 22 As the diagnostic criteria for the AUS category continue to be refined and standardized between institutions, the ROM for this category will likely demonstrate less variability. In addition to the 6 established categories, we created the "indeterminate" category, encompassing AUS, SUMP, and SFM. This indeterminate category was created to represent a category of diagnostically indefinite cases causing uncertainty to even the most experienced cytopathologists. As proven from thyroid cytology, this set of indeterminate cases in salivary gland cytology can pose similar challenges in management. Thus, we analyzed the indeterminate lesions to gain a better understanding of the category's significance. In the indeterminate category, the most common malignant follow-up was lymphoma (14 cases; 42%) ( Table 4 ). In keeping with this finding, Wang et al assessed 504 AUS diagnoses from 5 different institutions and identified lymphoma as the most common malignant diagnosis on follow-up (60.6%). 22 Moreover, the group also demonstrated that "lymphoid-rich" scenarios represented 44.8% of the atypical diagnoses. For lymphoma, the challenge lies in cytomorphologically distinguishing between a neoplastic and a reactive lymphoid process, and therefore the addition of FC or ancillary testing on a cell block study can greatly improve the sensitivity and specificity to 100% and 83%, respectively.
22
The most common benign lesions within the indeterminate category were benign inflammatory/nonneoplastic processes (7 cases; 21%) such as chronic sialadenitis (2 cases), benign lymphoid tissue (3 cases), lymphoepithelial cyst (1 case), and foreign body reaction (1 case), followed closely by benign neoplasms (mainly PA [5 cases]) (Table 4) . This finding is similar to those of the study by Wang et al, in which benign inflammatory and nonneoplastic disease comprised 16.2% of the atypical lesions. 22 Chronic sialadenitis and nonspecific sialadenosis are known pitfalls in salivary gland cytology 9, 15 due to the presence of reactive atypia, especially with chronic sialadenitis, leading to an indeterminate interpretation and possible unnecessary surgical excision. To the best of our knowledge, there are no ancillary studies to date that can definitively aid in diagnosing chronic sialadenitis. A clinicopathologic and radiologic correlation is the current standard of practice in the diagnosis of chronic sialadenitis on FNA specimens. Similar to any other classification system in cytopathology, an initial challenge in implementing the MSRSGC is the different levels of experience and practice patterns of cytopathologists within and between institutions. This potentially could lead to interobserver variability in the categorization of the salivary gland lesions and can skew the data sets. 18 We believe that this challenge will be overcome as the system is implemented in more centers and the knowledge level and expertise regarding the interpretation of the proposed categories improve. Certain limitations exist in the current study, most notably its retrospective design. However, currently, in several institutions including ours, the MSRSGC has not yet been adopted and data continue to be collected. Therefore, to our knowledge, the majority of the studies concerning the MSRSGC have been retrospective studies. 9, 15, 21, 22 With the atlas having been published recently and as the MSRSGC is becoming increasingly used, more prospective data will become available. Also, the findings in our study may not be generalized with other academic institutions and community practices due to inherent differences in practice patterns, patient demographics, and the heterogeneity of salivary gland lesions, which is an inherent limitation in such studies.
We attempted to retrospectively examine the validity of applying the MSRSGC in the study institution. As a future direction, we hope to analyze the cytomorphology of the false-positive and false-negative cases and the cases in the indeterminate category in comparison with their final surgical outcome, in an attempt to identify key cytomorphologic features of these select cases and pitfalls in their diagnosis.
The results of the current study are in keeping with recent studies highlighting the MSRSGC as a useful tiered classification system for reporting salivary gland cytology for appropriate clinical management, and add to the growing data set in the literature. The establishment of the indeterminate category increases our awareness of lesions that prove to be diagnostically challenging on FNA and the need for clinical and radiologic correlation and the development and use of ancillary studies to refine this category further to provide good patient care and outcomes.
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